Literature DB >> 11411734

Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension.

R Asmar1, M Safar, P Queneau.   

Abstract

Pharmacologic studies in hypertension often describe blood pressure (BP) reductions in placebo control groups. This placebo effect is currently debated, as it seems to be related to BP measurement methods and as a regression to the mean phenomenon may lead to misinterpretation. Furthermore, data on pulse pressure are lacking. This study was designed to evaluate the placebo effect on BP and to differentiate it from regression to the mean. According to a crossover design, 26 mild-to-moderate hypertensive patients who were treated with placebo or given no treatment were followed-up for 1 month. Clinic and ambulatory BP was assessed at baseline and at the end of each 1-month period. Placebo administration resulted in significant reductions in clinic systolic, diastolic, and mean BP (P < .01), ambulatory 24-h SBP (P < .05), and daytime systolic, diastolic, and mean BP (P < .01, P < .05, P < .01, respectively). No significant differences were noted for pulse pressure and heart rate or between BP values measured at baseline and after 1 month without treatment. Despite a significant correlation between changes in clinic and ambulatory BP, the scatter of individual data suggests that the placebo response observed with one method cannot be systematically extrapolated to the other method. This study conclusively shows the effect of placebo in mild-to-moderate hypertension on both clinic and ambulatory systolic, diastolic, and mean BP, in which it has been shown to differ from the regression to the mean phenomenon. This effect was not observed for pulse pressure or heart rate.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11411734     DOI: 10.1016/s0895-7061(00)01286-3

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  22 in total

Review 1.  Pulse pressure: an important tool in cardiovascular pharmacology and therapeutics.

Authors:  Roland Asmar; Michel Safar; Patrice Queneau
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Regression to the mean. A threat to exercise science?

Authors:  Roy J Shephard
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

Review 3.  Placebo: misunderstandings and prejudices.

Authors:  Matthias Breidert; Karl Hofbauer
Journal:  Dtsch Arztebl Int       Date:  2009-11-13       Impact factor: 5.594

4.  Cardiovascular impact of exercise and drug therapy in older hypertensives with coronary heart disease: PREHACOR study.

Authors:  Jean-Jacques Mourad; Nicolas Danchin; Jacques Puel; Hervé Gallois; Jérôme Msihid; Michel E Safar; Hirofumi Tanaka
Journal:  Heart Vessels       Date:  2008-02-14       Impact factor: 2.037

Review 5.  Placebo interventions for all clinical conditions.

Authors:  Asbjørn Hróbjartsson; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 6.  The placebo effect: illness and interpersonal healing.

Authors:  Franklin G Miller; Luana Colloca; Ted J Kaptchuk
Journal:  Perspect Biol Med       Date:  2009       Impact factor: 1.416

Review 7.  The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.

Authors:  Helena M de Wit; Maarten Te Groen; Maroeska M Rovers; Cees J Tack
Journal:  Br J Clin Pharmacol       Date:  2016-04-22       Impact factor: 4.335

Review 8.  [Clinical significance of the placebo effect].

Authors:  J Oeltjenbruns; M Schäfer
Journal:  Anaesthesist       Date:  2008-05       Impact factor: 1.041

9.  Impact of GNB3-C825T, ADRB3-Trp64Arg, UCP2-3'UTR 45 bp del/ins, and PPARγ-Pro12Ala polymorphisms on Bofutsushosan response in obese subjects: a randomized, double-blind, placebo-controlled trial.

Authors:  Junghyun Park; Shambhunath Bose; Sun-Woo Hong; Dong-Ki Lee; Jae-Wook Yoo; Chi-Yeon Lim; Myeongjong Lee; Hojun Kim
Journal:  J Med Food       Date:  2014-05       Impact factor: 2.786

10.  Misclassification and discordance of measured blood pressure from patient's true blood pressure in current clinical practice: a clinical trial simulation case study.

Authors:  Yuyan Jin; Robert Bies; Marc R Gastonguay; Norman Stockbridge; Jogarao Gobburu; Rajanikanth Madabushi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-09       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.